RENEO PHARMACEUTICALS INC (RPHM) Stock Price & Overview
NASDAQ:RPHM • US75974E1038
Current stock price
The current stock price of RPHM is 1.82 USD. Today RPHM is up by 5.2%. In the past month the price increased by 27.27%. In the past year, price decreased by -77.97%.
RPHM Key Statistics
- Market Cap
- 24.279M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.69
- Dividend Yield
- N/A
RPHM Stock Performance
RPHM Stock Chart
RPHM Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to RPHM. When comparing the yearly performance of all stocks, RPHM is a bad performer in the overall market: 89.02% of all stocks are doing better.
RPHM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RPHM. RPHM has a great financial health rating, but its profitability evaluates not so good.
RPHM Earnings
RPHM Forecast & Estimates
7 analysts have analysed RPHM and the average price target is 2.3 USD. This implies a price increase of 26.1% is expected in the next year compared to the current price of 1.82.
RPHM Groups
Sector & Classification
RPHM Financial Highlights
Over the last trailing twelve months RPHM reported a non-GAAP Earnings per Share(EPS) of -1.69. The EPS increased by 27.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.83% | ||
| ROE | -73.56% | ||
| Debt/Equity | 0 |
RPHM Ownership
RPHM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.94 | 371.899B | ||
| AMGN | AMGEN INC | 15.18 | 189.187B | ||
| GILD | GILEAD SCIENCES INC | 15.79 | 174.329B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.5 | 113.007B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.91 | 79.873B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.04 | 45.013B | ||
| INSM | INSMED INC | N/A | 33.111B | ||
| NTRA | NATERA INC | N/A | 30.421B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.133B | ||
| BIIB | BIOGEN INC | 11.08 | 26.264B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.89 | 25.357B | ||
| MRNA | MODERNA INC | N/A | 20.956B | ||
| INCY | INCYTE CORP | 12.61 | 19.441B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RPHM
Company Profile
Reneo Pharmaceuticals, Inc. is a clinical-stage company, which engages in the research and development of therapies for rare genetic mitochondrial diseases. The company is headquartered in Irvine, California and currently employs 8 full-time employees. The company went IPO on 2021-04-09. The firm is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The firm's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The firm is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).
Company Info
IPO: 2021-04-09
RENEO PHARMACEUTICALS INC
18575 Jamboree Road, Suite 275-S
Irvine CALIFORNIA US
Employees: 8
Phone: 18582830280
RENEO PHARMACEUTICALS INC / RPHM FAQ
Can you describe the business of RENEO PHARMACEUTICALS INC?
Reneo Pharmaceuticals, Inc. is a clinical-stage company, which engages in the research and development of therapies for rare genetic mitochondrial diseases. The company is headquartered in Irvine, California and currently employs 8 full-time employees. The company went IPO on 2021-04-09. The firm is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The firm's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The firm is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).
What is the stock price of RENEO PHARMACEUTICALS INC today?
The current stock price of RPHM is 1.82 USD. The price increased by 5.2% in the last trading session.
What is the dividend status of RENEO PHARMACEUTICALS INC?
RPHM does not pay a dividend.
What is the ChartMill technical and fundamental rating of RPHM stock?
RPHM has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for RPHM stock?
7 analysts have analysed RPHM and the average price target is 2.3 USD. This implies a price increase of 26.1% is expected in the next year compared to the current price of 1.82.
What is the market capitalization of RPHM stock?
RENEO PHARMACEUTICALS INC (RPHM) has a market capitalization of 24.28M USD. This makes RPHM a Nano Cap stock.
When does RENEO PHARMACEUTICALS INC (RPHM) report earnings?
RENEO PHARMACEUTICALS INC (RPHM) will report earnings on 2024-11-06, before the market open.